Patient-Oriented Evidence That Matters

Short-Term Low Back Pain Relief with Placebo


Am Fam Physician. 2021 Jan 15;103(2):online.

Clinical Question

Is placebo effective in patients with low back pain?

Bottom Line

Over three weeks, patients with long-term low back pain who knowingly took placebo twice a day reported less pain and disability than those continuing with treatment as usual. This is not the only study to show the benefit of placebo. Whether the benefit persists is not known. A nonprescription placebo (Zeebo) is available, or pharmacists can prepare placebo capsules. (Level of Evidence = 2b)


The authors enrolled 127 patients with long-term low back pain. More than 70% of enrollees reported having back pain for more than five years. The average age was 59 years and 60% were women. Initial pain scores were approximately 5 out of a possible 10, and roughly 20% of the patients were treated with analgesics at the time of enrollment. The patients were told before enrollment that the study would involve placebo treatment and were shown a video on the beneficial effects of placebo. They were then randomized, with allocation assignment unconcealed, to receive existing care or existing care plus placebo to be taken twice daily for 21 days. The patients were told it was placebo. At the end of the study, a composite pain intensity score—comprising minimum, maximum, and average pain intensities during the past seven days on an 11-point scale—dropped more with placebo treatment than with existing care alone (0.62 vs. 0.11; P = .001), and subjective disability scores improved to a greater extent with placebo (3.21 decrease vs. 0.65 increase; P = .02). Objective mobility or anxiety and stress scores were not affected. The researchers did not mask the enrolling investigator to the treatment assignment at the time of enrollment (unconcealed allocation); randomization produced an imbalance in body mass index between the groups, which might have been due to chance or to selective enrollment of patients.

Study design: Randomized controlled trial (nonblinded)

Funding source: Government

Allocation: Unc

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article